BLCO News & Events

Bausch + Lomb Corporation announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite Vision Enhancement System. "Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of its dual-port design, 100% open duty cycle and cutting speed of 15,000 cuts per minute," said Wayne Caulder, vice president and general manager, North America Surgical, Bausch + Lomb.

Bausch + Lomb announced European commercial availability of the preloaded enVista Envy full range of vision intraocular lens, which offers excellent dysphotopsia tolerance on the widely used enVista IOL platform. A multicenter, randomized and controlled clinical trial evaluating 332 subjects demonstrated excellent long-term outcomes with the enVista Envy IOL in the U.S. On average, 86.1 % of patients reported little to no bothersomeness for dysphotopsia, showing an impressive tolerance profile overall. In a Canadian clinical study evaluating 110 subjects, 95.4% of patients reported little to no difficulty viewing close objects, and 93 % were completely to moderately satisfied with their vision post-surgery.